Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy

Pharmacogenomics Journal

Volumn 13, Issue 3, 2013, Pages 251-256

  Becker, M L ^a   Elens, L L F S ^a   Visser, L E ^a   Hofman, A ^a   Uitterlinden, A G ^a   Van Schaik, R H N ^a,b   Stricker, B H ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STAR Medical Diagnostic Center   (Netherlands)

^c Drug Safety Unit   (Netherlands)

Author keywords

atorvastatin; ATP binding cassette sub family C member 2; multidrug resistance associated protein 2; pharmacogenetics; Simvastatin

Indexed keywords

ALANINE; ATORVASTATIN; CHOLESTEROL; CYTOCHROME P450 3A4; HYPOCHOLESTEROLEMIC AGENT; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 2; SIMVASTATIN; THREONINE;

ADULT; ADVERSE OUTCOME; ARTICLE; CHOLESTEROL BLOOD LEVEL; CYP3A4 1B GENE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE PROTEIN 1 GENE; MULTIDRUG RESISTANCE PROTEIN 2 GENE; ORGANIC ANION TRANSPORTER 2 GENE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PYRROLES; SIMVASTATIN;

EID: 84878241152     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.59     Document Type: Article

References (23)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Pharmacogenomics 2009; 10: 1743-1751.
3. Rodrigues AC. Efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab Toxicol 2010; 6: 621-632.
4. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359: 789-799.
5. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006; 112: 457-473.
6. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236.
7. Kivisto KT, Grisk O, Hofmann U, Meissner K, Moritz KU, Ritter C et al. Disposition of oral and intravenous pravastatin in MRP2-deficient TR-rats. Drug Metab Dispos 2005; 33: 1593-1596.
8. Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 2011; 39: 1196-1202.
9. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J 2011; 11: 25-34.
10. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf 2010; 19: 75-81.
11. Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, Kuipers EJ et al. The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 2009; 24: 553-572.
12. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 2008; 371: 1505-1512.
13. The International HapMap Project. Nature 2003; 426: 789-796.
14. 0-untranslated-region haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the Rotterdam study. Am J Hum Genet 2005; 77: 807-823.
15. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-1169.
16. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
17. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002; 72: 474-489.
18. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87: 1322-1330.
19. Chen C, Lin J, Smolarek T, Tremaine L. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab Dispos 2007; 35: 1725-1729.
20. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005; 33: 537-546.
21. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008; 84: 457-461.
22. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005; 78: 551-558.
23. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 2011; 89: 210-216.